NCT06046833
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
Recruiting · Not Applicable · Samita Garg · registry updated 2026-08-03
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
Inclusion
- Over the age of 18 years.
- Hemoglobin A1c ≤11% within the last 6 months.
- Patients with diagnosis of type 1 Diabetes or type 2 Diabetes for at least one year.
- Normal thyroid-stimulating hormone (TSH) within the last year.
- No episodes of diabetic ketoacidosis (DKA), Hyperosmolar Hyperglycemic Status (HHS), or hypoglycemia in the past 2 weeks requiring ER visit or hospitalization.
- Symptoms of gastroparesis have been present for at least the past 3 months, in patients with gastroparesis.
Exclusion
- Hemoglobin A1c of \>11% at enrollment.
- Advanced chronic kidney disease (serum creatinine of \>2 mg/dL or estimated glomerular filtration rate (eGFR) \<30mL/min/1.73m² using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).
- Advanced and significant cardiovascular disease or unstable angina.
- Advanced liver disease that may affect glucose profiles.
- Post-transplant patients.
- History of gastric surgery.